Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy By: TalkMarkets January 20, 2024 at 14:40 PM EST Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line. Read More >> Related Stocks: Adagene Inc ADR Astrazeneca Plc ADR Carsgen Therapeutics Hldgs Ltd Merck & Co Windtree Therapeutics Inc Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy By: TalkMarkets January 20, 2024 at 14:40 PM EST Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line. Read More >> Related Stocks: Adagene Inc ADR Astrazeneca Plc ADR Carsgen Therapeutics Hldgs Ltd Merck & Co Windtree Therapeutics Inc